Full-Time

Head of Neuromuscular Therapeutic Area

US Medical Affairs

Posted on 11/1/2025

argenx

argenx

1,001-5,000 employees

Biotech immunology company developing therapeutic antibodies

Compensation Overview

$296k - $444k/yr

+ Short-term incentive + Long-term incentive

Boston, MA, USA

Hybrid

Hybrid role; ~40% travel; based in Boston, MA.

Category
Medical, Clinical & Veterinary (3)
, ,
Required Skills
Management
Requirements
  • MD, PhD or PharmD with significant team leadership experience
  • 10+ years of industry experience
  • Expert in US healthcare dynamics including patient journey, access, regulatory requirements and compliance/ethics
  • Experience in neurology, immunology or rheumatology and/or specific biopharmaceutical industry experience required
  • Willingness to travel, approximately 40% of time
Responsibilities
  • Lead team of medical directors and field medical teams with accountability for the development and implementation of the Medical Affairs strategy, plan and activities within the NM TA (various disease such as MG, CIDP, Myositis, MMN, etc), aligning with cross-functional colleagues including Global Medical Affairs, Marketing, Market Access, Patient services, Global Clinical Development, Global Clinical Operations, Neuromuscular Expert etc.
  • Ownership in leading, developing and maintaining the highest scientific and medical expertise with all diseases and products/assets within the NM TA
  • Proactively drive the identification and development of productive collaborations with clinical experts, KOLs, other important customers and stakeholders, including professional organizations for evidence generation, communication and insight generation
  • Lead NM teams to initiate and support high impact medical activities, such as advisory boards, congress symposia, hospital formulary meetings, speaker development programs and payer market access education focused on changing outcomes in patient care
  • Support the development and execution of publication plans, aligned with scientific communications, to ensure timely and impactful data dissemination
  • Identify and implement appropriate high-impact medical research projects to support the business objectives, including argenx sponsored and investigator-initiated projects, post-hoc analysis and clinical collaborations
  • Coordinate the implementation of medical affairs practices, and systematic information gathering to assess new indications, the treating community, patient pathways, diagnostic practices and management strategies in relevant disease areas
  • In conjunction with clinical development and operations support clinical study development, feasibility assessment, initiation and ongoing management to achieve recruitment and study objectives
  • Be an organizational leader and develop collaborative relationships with cross functional teams in US and globally
  • Foster an inclusive and empowered team environment within NM TA medical affairs, including with Scientific Communications, HEOR, Medical information, Medical Operations and field-based Medical Research Liaison Team, ensuring strategic and tactical alignment
  • Support cross-functional teams to ensure operations are patient-focused, including rapidly responding to internal and external requests and provide medical affairs support to all stakeholders
  • Accountability to attend national and international scientific meetings and congresses to gather intelligence, assist personal education, ensuring to utilize these opportunities to develop relationships with important customers as well as deliver an impactful congress presence for argenx
  • Conduct and provide medical leadership to training programs to field-based teams and other functions and prepare staff to handle interactions with customers
  • Systematically capture, distill and proactively communicate key HCP/KOL insights and activities within argenx and Senior Management
  • Ensure medical accuracy of Medical Affairs activities, including advisory boards and scientific expert meetings, studies, publications, scientific congress activities, medical education, medical information content and medical field programs
  • Ensure all medical affairs activities maintain the highest standards, comply with applicable pharmaceutical regulation, as well as argenx policies and procedures
Desired Qualifications
  • Rare disease experience desirable
  • Medical Affairs, Clinical Practice and/or Clinical Development Experience in Neurology preferred

argenx develops antibody therapies to treat autoimmune diseases and cancer by translating scientific discoveries in immunology into therapeutic antibodies. Its work centers on R&D and then licensing and collaborations for commercialization, with cusatuzumab being developed with Janssen R&D to target hematological cancers such as leukemia. The company funds and accelerates discovery mainly through partnerships and licenses, bringing products to market via partner-based commercialization rather than building its own sales force. Its goal is to advance antibody-based treatments for serious autoimmune diseases and cancer by turning scientific insights into clinically useful therapies through industry and academic collaborations.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Ghent, Belgium

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 product sales reached $1.3 billion, up 63%.
  • The May 10, 2026 seronegative gMG FDA decision can expand VYVGART.
  • Myositis and MMN readouts in 2026 diversify growth beyond MG.

What critics are saying

  • VYVGART still drives almost all growth, creating dangerous revenue concentration.
  • A restrictive seronegative gMG ruling would stall the next growth leg.
  • Negative myositis or MMN data would weaken Vision 2030 expansion plans.

What makes argenx unique

  • VYVGART is the only gMG therapy offered both IV and SC.
  • argenx built a first-in-class FcRn antibody-fragment platform for severe autoimmune diseases.
  • Karen Massey's 2026 CEO succession preserves Vision 2030 continuity.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at argenx who can refer or advise you

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Investing.com
Apr 13th, 2026
Argenx and Vertex Pharmaceuticals named BofA top biotech picks for 2026.

Argenx and Vertex Pharmaceuticals named BofA top biotech picks for 2026. Published 04/13/2026, 06:16 AM (C) Reuters. Investing.com - Bank of America has reaffirmed Argenx (NASDAQ:ARGX) and Vertex Pharmaceuticals (NASDAQ:VRTX) as its top large-cap biotech picks for 2026, with price targets of $1,013 and $598, respectively. For Argenx, BofA cited strong commercial performance of Vvygart in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, driven by expansion into earlier treatment lines and growing real-world experience. The firm highlighted upcoming phase 3 results for efgartigimod in myositis in the third quarter and empasiprubart in multifocal motor neuropathy in the fourth quarter as potential catalysts. For Vertex, BofA emphasized the strength of the cystic fibrosis franchise in providing cash flow to support pipeline expansion. The firm identified the rare kidney disease franchise as a key long-term growth driver, noting positive data for povetacicept in IgA nephropathy. Among commercial small- and mid-cap picks, BofA selected KalVista Pharmaceuticals (NASDAQ:KALV) with a $32 price target and Rhythm Pharmaceuticals (NASDAQ:RYTM) with a $149 price target. KalVista's Ekterly was approved in July 2025 as the first on-demand hereditary angioedema therapy, while Rhythm's Imcivree became the first approved therapy for acquired hypothalamic obesity in March. For pre-commercial small- and mid-cap stocks, BofA named Ocular Therapeutix (NASDAQ:OCUL) with a $27 price target and Bicara Therapeutics (NASDAQ:BCAX) with a $35 price target as top picks. Should you invest $2,000 in VRTX right now? ProPicks AI evaluates VRTX alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias - it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if VRTX is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?

GlobeNewswire
Apr 7th, 2026
Folia Health launches app-based study to unlock novel real-world evidence of symptom burden and unmet need for patients and caregivers in CIDP.

Folia Health launches app-based study to unlock novel real-world evidence of symptom burden and unmet need for patients and caregivers in CIDP. April 07, 2026 10:00 ET | Source: Folia Health BOSTON, April 07, 2026 (GLOBE NEWSWIRE) - Folia Health today announced a collaboration with argenx to launch a first-of-its-kind, at-home observational real-world evidence initiative supporting individuals living with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). "Our team at Folia shows up to work every day to translate the lived experience of patients into research-grade data that can be used to inform the therapies..." The study represents the first real-world data program designed to capture the at-home experiences of individuals with CIDP and their caregivers. Designed in partnership with patients and caregivers, the initiative leverages Folia's home-reported outcomes (HROs) platform, enabling participants to select and track the symptoms that matter most to them while documenting their individualized treatment plans. Over time, the platform captures symptom severity, treatment utilization, and other aspects of daily disease management directly from patients over an initial six-month period. "Our team at Folia shows up to work every day to translate the lived experience of patients into research-grade data that can be used to inform the therapies available to help people. With our partners at argenx, we are very motivated to be able to describe the diverse experiences of people living with CIDP, including difficulties with nerve pain and symptom flare ups. We hope that this work will pave the way for care plans that enable people with CIDP and their caregivers to achieve a better quality of life with less interference from their disease." said Nell Meosky Luo, the CEO & Founder of Folia Health. HROs tracked by patients and caregivers provide a continuous view of what happens between clinic visits, overlaying tracked symptoms and treatments with real-world quality-of-life impacts such as the ability to work, engage in everyday activities, and navigate life independently. Through the Folia platform, CIDP patients and caregivers can actively engage with their own study data and gain deeper insights into their symptom burden, treatment effects, and acute health events. The Folia app generates tracking summary reports that let patients easily visualize changes over time, including symptom severity trends, flare frequency, and treatment responses. Calendar filtering tools further enable patients to see when symptoms, flares, and other health events occur, which may help them identify patterns and understand how treatments may influence daily life. The platform can overlay treatment usage with symptom severity, and patients can export visual reports to share meaningful insights with their care teams. About Folia Health: Folia Health is a patient-led health company and the pioneer of home-reported outcomes (HROs), transforming lived health experiences into valuable structured data insights to advance research and personalized care. The company's platform is built on the belief that the knowledge of patients and caregivers is the missing piece to enable precise, individualized care and high-impact research. Through a useful platform, radical transparency, explicit consent protocols, and data dividend payments, Folia bridges the gap between patients, clinicians, and researchers while maintaining the highest standards of data privacy and patient autonomy. Founded in 2016 by family caregivers and based in Boston, Folia works with individuals across chronic and rare conditions to generate clinical-grade real-world evidence. For more information, visit www.foliahealth.com. Folia Health Contact: Matt Berry Director of Marketing [email protected]

The Associated Press
Mar 20th, 2026
argenx schedules shareholder meeting for 6 May, proposes board changes

argenx, a global immunology company, will hold its Annual General Meeting on 6 May 2026 at 13:00 CET at the Hilton Amsterdam Schiphol in the Netherlands. The agenda includes routine items such as adopting 2025 annual accounts and an advisory vote on the remuneration report. Several board changes are proposed, including appointing Karen Massey as executive director and Tim Van Hauwermeiren as non-executive director, both for four-year terms. Ana Céspedes, Camilla Sylvest and Pamela Klein are up for re-appointment. Jim Daly will retire as non-executive director and Chair of the Commercialisation Committee, effective 6 May 2026, after serving since May 2018. The board is examining succession options for his role.

Yahoo Finance
Mar 17th, 2026
Argenx shares boosted to $1,060 as Vyvgart revenues surge 74% to $1.29B

Argenx SE has received positive analyst coverage following strong Q4 results. Oppenheimer raised its price target to $1,060 from $1,040 on 26 February, maintaining an Outperform rating, whilst BofA Securities increased its target to $1,013 from $1,006, keeping a Buy rating. The Netherlands-based biotechnology company reported earnings per share of $8.02, surpassing expectations of $5.95, with revenue of $1.29 billion slightly exceeding the $1.28 billion forecast. Vyvgart revenues totalled $1.29 billion in Q4 2025, marking a 74% year-on-year increase. According to Oppenheimer, Vyvgart's myositis readout in Q3 could unlock an additional 20,000-patient opportunity. BofA Securities ranked Argenx as a top pick whilst maintaining flat Vyvgart sales projections for Q1 2026.

GlobeNewswire
Mar 16th, 2026
Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics

Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics...

INACTIVE